If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
== Regulations for pet food ingredients == Aside from the CFIA, which makes the use of specified risk materials illegal, pet food ingredients do not need to be approved by any regulatory body in Canada. However, if manufacturers plan to expand into the U.S. market, they must adhere to regulations imposed by each state, or comply with guidelines established by the American Association of Feed Control Officials (AAFCO). These guidelines will provide country-wide acceptable ingredients, and nutritional recommendations based on research collected by the National Research Council (NRC). As of August 2021, AAFCO has approved the use of Black Soldier Fly (BSF) insects in pet food - specifically for adult dogs. The use of insects in feed in the European Union was previously prohibited under an act called "TSE Regulation" (Article 7 and Annex IV of Regulation 999/2001) that bans the use of animal protein in animal feed. In July 2017 this regulation was revised and partially lifts the ban on animal proteins, allowing insects to be included in fish feed. This was coupled with another change that reclassified insects in the European Union (EU) catalogue of feed materials. This change specifically refers to fats and proteins from insects instead of classifying them under a broad title of animal products. Due to this change, producers now must list the species and life stage of the insect on their product. Novel pet food ingredients in Europe must also follow certain stringent regulations, making approval of new ingredients a lengthy process.
In 1975, Domino's faced a lawsuit by Amstar Corporation, the maker of Domino Sugar, alleging trademark infringement and unfair competition. On May 2, 1980, the Fifth Circuit Court of Appeals in New Orleans found in favor of Domino's Pizza. During the lawsuit, Domino's opened fifteen new stores under the name Pizza Dispatch, while also converting other stores to the name.
Severo-Kurilsky District (Severo-Kurilsk) Kurilsky District (Kurilsk) Yuzhno-Kurilsky District (Yuzhno-Kurilsk) Japan maintains a claim to the three islands of Kunashir, Iturup, and Shikotan, and the Habomai Islands, together called the Northern Territories. In addition, the Japanese government claims that the Kuril Islands, other than the Northern Territories and South Karafuto, are undetermined areas under international law because the San Francisco Peace Treaty does not specify where they belong and the Soviet Union did not sign it. On 8 February 2017 the Russian government gave names to five previously unnamed Kuril islands in Sakhalin Oblast: Derevyanko Island (after Kuzma Derevyanko, 43°22′8″N 146°1′3″E), Gnechko Island (after Alexey Gnechko, 43°48′5″N 146°52′1″E), Gromyko Island (after Andrei Gromyko, 46°14′1″N 150°36′1″E), Farkhutdinov Island (after Igor Farkhutdinov, 43°48′5″N 146°53′2″E) and Shchetinina Island (after Anna Shchetinina, 46°13′7″N 150°34′6″E).
Source 2 is a video game engine developed by Valve. The engine was announced in 2015 as the successor to the original Source engine, with the first game to use it, Dota 2, being ported from Source that same year. Other Valve games such as Artifact, Dota Underlords, Half-Life: Alyx, Counter-Strike 2, and Deadlock have been produced with the engine.
Sources: en.wikipedia.org
=== Pharmacological regulation === In certain conditions such as in the case of cardiac disease, the Na+/K+-ATPase may need to be inhibited via pharmacological means. A commonly used inhibitor used in the treatment of cardiac disease is digoxin (a cardiac glycoside) which essentially binds "to the extracellular part of enzyme i.e. that binds potassium, when it is in a phosphorylated state, to transfer potassium inside the cell" After this essential binding occurs, a dephosphorylation of the alpha subunit occurs which reduces the effect of cardiac disease. It is via the inhibiting of the Na+/K+-ATPase that sodium levels will begin to increase within the cell which ultimately increases the concentration of intracellular calcium via the sodium-calcium exchanger. This increased presence of calcium is what allows for the force of contraction to be increased. In the case of patients where the heart is not pumping hard enough to provide what is needed for the body, use of digoxin helps to temporarily overcome this.
=== Switzerland === Beak trimming in Switzerland is legal but regulated; it is expected that the practice will be prohibited in the near future. Although the use of cages for layer hens was prohibited in 1992, by 2000 still 59% of flocks (61% of hens) was still debeaked.
=== Employee insider trading scandal === On the evening of September 29, 2016, Hanmi announced the Roche deal, causing its stock to rise; Hanmi was notified by Boehringer that evening that Boehringer was terminating their deal, and the company announced the termination on the morning of the 30th, causing its stock to crash. Hanmi's offices were raided by Korean regulatory authorities in mid-October based on evidence that insider knowledge of the Boehringer termination was passed to third parties, who shorted the stock prior to the announcement on the 30th. In December three Hanmi employees were among 17 people indicted for insider trading; 25 people were fined, and 45 people were found to have made illegal trades that took around 3.3 billion won ($2.83 million) in profits based on the information.
Duke of Modena (Lord 1288, Duke 1452) and Reggio (nell'Emilia) (Lord 1289, Duke 1452) Duke of Ferrara (Lord 1264, Duke 1471–1597) Duke of La Mirandola (1710), Massa (1829) and Guastalla (1847) Prince of the Holy Roman Empire, Prince of Carpi (Count 1530, Prince 1535), Correggio (1635), San Martino in Rio (1752) and of Carrara (1829), Marquis of Montecchio (1597, marquessate in 1569), of Scandiano (1645) and La Concordia (1710) Count palatine of Novellara (1737) and Bagnolo (1737), Count of Jeno ed Avad (Hungary, 1726) Lord of Sassuolo (1373), San Martino in Spino (1710), Campogalliano (1752), Castellarano (1752), Rodeglia (1752), Ieno and San Cassiano
Over 500 mineral blocks are present in Jammu and Kashmir, 261 of which are in the Kashmir Division alone. Kishtwar is known as the 'land of sapphire and saffron'. Resources such as timber, herbs and medicinal shrubs, edibles such as mushroom, chilgoza, black zeera, and saffron are available in the forests. The sapphire reserve mines of Machail, Paddar are a source of mineral wealth. Jammu and Kashmir is the only administrative unit in India with a large amount of borax and sapphire resources. It possesses 36% of the graphite, 21% marble and 14% of gypsum present in India. Coal, limestone and magnesite are found scattered among the different districts of the union territory. Other minerals of significance that occur are bauxite, ball clay and china clay in Udhampur; bentonite in Jammu; diaspore in Rajouri and Udhampur; graphite in Baramulla; lignite and marble in Kupwara; quartz and silica sand in Anantnag, Doda, and Udhampur; and quartzite in Anantnag district. In addition, the Department of Geology and Mining has determined the presence of minerals such as magnetite, dolomite, fuel mineral, decorative building stones, slate, and gemstones. All are materials with commercial and industrial uses in many products and factories. In the fiscal year 2019–20, total exports from Jammu and Kashmir amounted to ₹188.18 million (equivalent to ₹240 million or US$2.5 million in 2026). The Jammu & Kashmir Bank, which is listed as a NIFTY 500 conglomerate, is based in the union territory. Jammu and Kashmir is one of the largest recipients of grants from the central government annually.
Sources: en.wikipedia.org
=== Other reactions === Thionyl chloride can engage in a range of different electrophilic addition reactions. It adds to alkenes in the presence of AlCl3 to form an aluminium complex which can be hydrolysed to form a sulfinic acid. Both aryl sulfinyl chlorides and diaryl sulfoxides can be prepared from arenes through reaction with thionyl chloride in triflic acid or the presence of catalysts such as BiCl3, Bi(OTf)3, LiClO4 or NaClO4. In the laboratory, a reaction between thionyl chloride and an excess of anhydrous alcohol can be used to produce anhydrous alcoholic solutions of HCl. Thionyl chloride undergoes halogen exchange reactions to give other thionyl species. Reactions with fluorinating agents such as antimony trifluoride give thionyl fluoride: 3 SOCl2 + 2 SbF3 → 3 SOF2 + 2 SbCl3 A reaction with hydrogen bromide gives thionyl bromide: SOCl2 + 2 HBr → SOBr2 + 2 HCl Thionyl iodide can likewise be prepared by a reaction with potassium iodide, but is reported to be highly unstable.
Cocaine is known to suppress hunger and appetite by increasing co-localization of sigma σ1R receptors and ghrelin GHS-R1a cell surface receptors, thereby increasing ghrelin-mediated signaling of satiety and possibly via other effects on appetitive hormones. Cocaine effects, further, are shown to be potentiated for the user when used in conjunction with new surroundings and stimuli, and otherwise novel environs.
For interpretation, first, look for single amino acid immonium ions (H2N+=CHR2). Corresponding immonium ions for amino acids are listed in Table 1. Ignore a few peaks at the high-mass end of the spectrum. They are ions that undergo neutral molecules losses (H2O, NH3, CO2, HCOOH) from [M+H]+ ions. Find mass differences at 28 Da since b-ions can form a-ions by loss of CO. Look for b2-ions at low-mass end of the spectrum, which helps to identify yn-2-ions too. Mass of b2-ions are listed in Table 2, as well as single amino acids that have equal mass to b2-ions. The mass of b2-ion = mass of two amino acid residues + 1.
=== Global food distribution === Along with Archer Daniels Midland, Bunge, and Cargill, the Louis Dreyfus Company is one of the four "ABCD" companies that dominate world agricultural commodity trading.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.